Biohaven (BHVN) shares were up over 4% in recent trading on Wednesday after the company said its two drug candidates are near market and it is doing phase three testing for four other indications.
BHV-4157 for the treatment of spinocerebellar ataxia and BHV-2000 for spinal muscular atrophy are closer to the market stage, according to the company.
The company is evaluating BHV-4157 as a treatment for patients with obsessive-compulsive disorder in a phase three study.
Other late-stage candidates include BHV-7000 for focal and generalized epilepsies and BHV-8000 for Parkinson's disease, Biohaven said.
Price: 16.29, Change: +0.50, Percent Change: +3.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.